The phase III trials for Invossa will enroll close to 1,020 patients at over 50 clinical sites across the US.
In addition to demonstrating significant pain and functional improvements, the company has designed the trials for Invossa to achieve a disease modifying osteoarthritis drug designation from the FDA.
Current OA patients suffer through many years of debilitating pain and reduced quality of life.
A single injection of Invossa could lead to more than two years of productive and pain free mobility, without the immediate need for surgery, and fill in this significant treatment gap.
Invossa is a first-in-class cell and gene therapy targeting OA of the knee through a single intra-articular injection.
Clinical trials held in the US and abroad have demonstrated pain relief and increased mobility, as well indicators towards decreased progression of OA and improvements in joint structure.
Kolon TissueGene's mission is to provide safe and effective therapies to patients by reducing pain and improving function associated with various orthopedic diseases and degenerative disorders.
The company has developed a first-in-class cell and gene therapy targeting osteoarthritis of the knee.
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress
Cumberland Pharmaceuticals reports ifetroban Phase 2 DMD heart disease trial results
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma